Skip to main content
Haematologica logoLink to Haematologica
. 2026 Oct 1;111(10):3546. doi: 10.3324/haematol.2026.289473

Erratum to: “Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia”

Salih Demir 1,2, Elena Boldrin 1-3, Qian Sun 1, Stephanie Hampp 4, Eugen Tausch 5, Cornelia Eckert 6, Martin Ebinger 7, Rupert Handgretinger 7, Geertruy te Kronnie 8, Lisa Wiesmüller 4, Stephan Stilgenbauer 5, Galina Selivanova 9, Klaus-Michael Debatin 1, Lüder Hinrich Meyer 1,✉
PMCID: PMC13628021  PMID: 42817752

In the published version of our article,1 there was a potential error and an omission.

(1) Figure 3C, PUMA and p21 panels.

By mistake, the p21 bands might have been included in Figure 3C instead of the PUMA bands. We correct this potential mistake and show here the correct western blot data with the relevant part of the legend.

(2) Conflicts of interest

A conflict-of-interest statement was provided by the authors and present in the version of the manuscript published online ahead of print (May 9, 2019), but by mistake of the publisher was not included in the finally published article. The omitted Disclosures statement is shown below.

Corrected part of Figure 3C.

Corrected part of Figure 3C.

Conformational and functional restoration of mutant p53 by APR-246. Expression of p53 transcriptional targets PUMA and p21 in TP53-mutant acute lymphoblastic leukemia upon APR-246 treatment. Western blot, exposure to a solvent control (CTRL), doxorubicin (DOX, 15 ng/ mL), or APR-246 (APR, 5 µM) for the indicated times. The results of one representative out of two independent experiments are shown. See also Online Supplementary Figure S3.

References

  • 1.Demir S, Boldrin E, Sun Q, et al. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(1):170-181. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Haematologica are provided here courtesy of Ferrata Storti Foundation

RESOURCES